Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
In a survey of the spectrum of mutational burdens in 27 types of cancers, there was a correlation between an increased mutational burden and the response to checkpoint inhibition of PD-1 and PD-L1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these studies are limited to particular cancer types and subsets of patients, due to difference in mutation load seen in different cancer types, and immune-related adverse effects of therapy may occur [93][94][95][96].”
From Cancer-on-chip models for metastasis: importance of the tumor microenvironment (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these markers have clinical utility in specific contexts, their predictive accuracy varies considerably across tumor histologies and patient populations.”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While high TMB and immune checkpoint molecule expression, including PD-L1, have been used as predictive biomarkers across different cancer types, they have limited clinical utility when considered in isolation88,101.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [88]
Experimental — accuracy not yet measuredIn the citing paper
“Although high TMB led to FDA approval, it should be noted that certain tumor types with moderate TMB carry relatively high response rates to ICT, such as clear cell RCC (128, 129).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [128]
In the citing paper
“Melanoma, lung, and bladder cancer, tumors commonly associated with an increased number of mutations due to environmental DNA damage, exhibit a stronger response to ICB (Yarchoan et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Yarchoan et al., 2017
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Cited by
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
Hellmann, M. D., Ciuleanu, T.-E., Pluzanski, A., Lee, J. S., Otterson, G. A., Audigier-Valette, C., Minenza, E., Linardou, H., Burgers, S., Salman, P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801946 · Cited by 3,063
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
B cells and tertiary lymphoid structures promote immunotherapy response
Helmink, B. A., Reddy, S. M., Gao, J., Zhang, S., Basar, R., Thakur, R., Yizhak, K., Sade-Feldman, M., Blando, J., Han, G., et al. (2020) · Nature · doi:10.1038/s41586-019-1922-8 · Cited by 2,731
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
“This may be the reason the subset of Merkel-cell carcinoma that is associated with the Merkel-cell polyomavirus has a moderate TMB [93] but amongst the highest response rates of any tumor type with anti-PD1 therapy [94].”
BackgroundSelf-citationMarabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Zhang, L., Li, Z., Skrzypczynska, K. M., Fang, Q., Zhang, W., O’Brien, S. A., He, Y., Wang, L., Zhang, Q., Kim, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.048 · Cited by 1,526
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
Rojas, L. A., Sethna, Z., Soares, K. C., Olcese, C., Pang, N., Patterson, E., Lihm, J., Ceglia, N., Guasp, P., Chu, A., et al. (2023) · Nature · doi:10.1038/s41586-023-06063-y · Cited by 1,432
Immune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353
“Yefarchoan and colleagues evaluated the correlation between TMB and the objective response rate (ORR) in 27 tumour types among patients, receiving anti-PD-1 or anti-PDL-1 therapy, and observed that some cancers such as MCC responded to therapy better than what was predicted by TMB, suggesting that the emergence of vir…”
BackgroundThe tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
Self-citationThe Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Cold Tumors: A Therapeutic Challenge for Immunotherapy
Bonaventura, P., Shekarian, T., Alcazer, V., Valladeau-Guilemond, J., Valsesia-Wittmann, S., Amigorena, S., Caux, C., & Depil, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00168 · Cited by 1,108
“LACK OF TUMOR ANTIGENS Tumor antigens can be divided into three main classes: tumor specific antigens (TSA), cancergermline antigens (CGA), and tumor associated antigens (TAA) (3).”
BackgroundCancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Neoadjuvant checkpoint blockade for cancer immunotherapy
Topalian, S. L., Taube, J. M., & Pardoll, D. M. (2020) · Science · doi:10.1126/science.aax0182 · Cited by 1,001
Braun, D. A., Hou, Y., Bakouny, Z., Ficial, M., Sant’ Angelo, M., Forman, J., Ross-Macdonald, P., Berger, A. C., Jegede, O. A., Elagina, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0839-y · Cited by 992
Immune-checkpoint inhibitors: long-term implications of toxicity
Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982
Molecular profiling for precision cancer therapies
Malone, E. R., Oliva, M., Sabatini, P. J. B., Stockley, T. L., & Siu, L. L. (2020) · Genome Medicine · doi:10.1186/s13073-019-0703-1 · Cited by 913
“The second cohort in microsatellite stable colorectal cancer with TMB between 11 and 22 mutations per megabase showed limited clinical benefit, leading to the closure of the arm [39, 167, 172].”
BackgroundInfluentialOverall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors
Sha, D., Jin, Z., Budczies, J., Kluck, K., Stenzinger, A., & Sinicrope, F. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0522 · Cited by 859
Tumour evolution in hepatocellular carcinoma
Craig, A. J., von Felden, J., Garcia-Lezana, T., Sarcognato, S., & Villanueva, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0229-4 · Cited by 823
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
Yi, M., Jiao, D., Xu, H., Liu, Q., Zhao, W., Han, X., & Wu, K. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0864-3 · Cited by 764
The Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
Cancer immunotherapy: Pros, cons and beyond
Tan, S., Li, D., & Zhu, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109821 · Cited by 688
Fridman, W. H., Meylan, M., Petitprez, F., Sun, C.-M., Italiano, A., & Sautès-Fridman, C. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00619-z · Cited by 657
Rolfo, C., Mack, P., Scagliotti, G. V., Aggarwal, C., Arcila, M. E., Barlesi, F., Bivona, T., Diehn, M., Dive, C., Dziadziuszko, R., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.06.017 · Cited by 683
Zhao, P., Li, L., Jiang, X., & Li, Q. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0738-1 · Cited by 682
“Comprehensive analysis of dMMR/ MSI-H, PD-L1, and TMB or a multivariable predictive model composed of 9 exome parameters (the DNA repair pathway status, the WNT pathway status, the number of TCR clones, the number of neoantigens, the HLA*A*1 and HLA*A*24 status, and the fractions of signatures 1A, 1B, and 6) resulted…”
MethodFares, C. M., Van Allen, E. M., Drake, C. G., Allison, J. P., & Hu-Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 653
Improving cancer immunotherapy through nanotechnology
Goldberg, M. S. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0186-9 · Cited by 628
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors
Marcus, L., Fashoyin-Aje, L. A., Donoghue, M., Yuan, M., Rodriguez, L., Gallagher, P. S., Philip, R., Ghosh, S., Theoret, M. R., Beaver, J. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0327 · Cited by 578
“Similar to microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) cancers, which typically express a large number of neoantigens (1, 2), TMB reflects the overall somatic genomic burden of mutations within a given tumor.”
BackgroundMolecular and histological correlations in liver cancer
Calderaro, J., Ziol, M., Paradis, V., & Zucman-Rossi, J. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.001 · Cited by 590
Schumacher, T. N., Scheper, W., & Kvistborg, P. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053402 · Cited by 574
Ready, N., Hellmann, M. D., Awad, M. M., Otterson, G. A., Gutierrez, M., Gainor, J. F., Borghaei, H., Jolivet, J., Horn, L., Mates, M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01042 · Cited by 581
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T. T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 545
“In support of this premise, the tumor types for which ICI therapy has proven to be most effective are those with a high TMB (13).”
Self-citationTranscriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H.-C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03752-4 · Cited by 543
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Bai, R., Lv, Z., Xu, D., & Cui, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00209-0 · Cited by 471
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Wang, Z., Duan, J., Cai, S., Han, M., Dong, H., Zhao, J., Zhu, B., Wang, S., Zhuo, M., Sun, J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.7098 · Cited by 471
Liu, Z., Wang, T., She, Y., Wu, K., Gu, S., Li, L., Dong, C., Chen, C., & Zhou, Y. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01398-4 · Cited by 450
“However, many patients respond poorly to ICBs and develop resistance to PD-1 therapy [5, 6].”
BackgroundIdentifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
“Following similar reports in other malignancies, a meta-analysis that included 27 tumor types treated with anti-PD-1 or anti-PD-L1 agents showed a significant correlation between the tumor mutation burden and the objective response rate in most types of cancer (Yarchoan et al., 2017).”
ResultEndocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Immunotherapy in colorectal cancer: current achievements and future perspective
Fan, A., Wang, B., Wang, X., Nie, Y., Fan, D., Zhao, X., & Lu, Y. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.64077 · Cited by 410
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
“org Clin Cancer Res; 27(5) March 1, 2021 1239”
BackgroundInfluentialDanaher, P., Warren, S., Lu, R., Samayoa, J., Sullivan, A., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 421
“Since then, it has been demonstrated that tumor types with higher median mutation burden tend to be more response to checkpoint inhibitors than tumors that harbor few mutations [10].”
BackgroundKlempner, S. J., Fabrizio, D., Bane, S., Reinhart, M., Peoples, T., Ali, S. M., Sokol, E. S., Frampton, G., Schrock, A. B., Anhorn, R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0244 · Cited by 391
“Goodman and colleagues [11] suggested a pantumor cutoff of 20 mutations per Mb, and Yarchoan and colleagues [103] have reported a nearly linear relationship between TMB and ORR.”
BackgroundFrom state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer
Nevala-Plagemann, C., Hidalgo, M., & Garrido-Laguna, I. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0281-6 · Cited by 393
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
Atkins, M. B., & Tannir, N. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.009 · Cited by 392
“Tumor mutational burden has been indicated as a predictive biomarker for checkpoint inhibitors in some solid tumors, but the association has been less definitive in RCC [77,78].”
BackgroundOvarian Cancer Immunotherapy and Personalized Medicine
Morand, S., Devanaboyina, M., Staats, H., Stanbery, L., & Nemunaitis, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126532 · Cited by 372
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
Johnson, D. B., Manouchehri, A., Haugh, A. M., Quach, H. T., Balko, J. M., Lebrun-Vignes, B., Mammen, A., Moslehi, J. J., & Salem, J.-E. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0617-x · Cited by 366
Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
Lin, A., Zhang, J., & Luo, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02039 · Cited by 358
Geoerger, B., Kang, H. J., Yalon-Oren, M., Marshall, L. V., Vezina, C., Pappo, A., Laetsch, T. W., Petrilli, A. S., Ebinger, M., Toporski, J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30671-0 · Cited by 357
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
Braun, D. A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E. M., Wu, C. J., & Choueiri, T. K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00455-z · Cited by 356
Exploring immunotherapy in colorectal cancer
Weng, J., Li, S., Zhu, Z., Liu, Q., Zhang, R., Yang, Y., & Li, X. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01294-4 · Cited by 355
Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response
Hu, F.-F., Liu, C.-J., Liu, L.-L., Zhang, Q., & Guo, A.-Y. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa176 · Cited by 354
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344
Implementing TMB measurement in clinical practice: considerations on assay requirements
Büttner, R., Longshore, J. W., López-Ríos, F., Merkelbach-Bruse, S., Normanno, N., Rouleau, E., & Penault-Llorca, F. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000442 · Cited by 345
Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Yang, K., Halima, A., & Chan, T. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00789-4 · Cited by 321
Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)
Bodor, J. N., Boumber, Y., & Borghaei, H. (2020) · Cancer · doi:10.1002/cncr.32468 · Cited by 329
“The number of somatic mutations varies significantly between different cancer types, with melanoma having some of the highest number of mutations and gastrointestinal cancers, such as pancreatic cancer and mismatchrepair–proficient colorectal cancer, having some the lowest.(51) NSCLC spans a range in mutational burden…”
BackgroundHIP1R targets PD-L1 to lysosomal degradation to alter T cell–mediated cytotoxicity
Wang, H., Yao, H., Li, C., Shi, H., Lan, J., Li, Z., Zhang, Y., Liang, L., Fang, J.-Y., & Xu, J. (2019) · Nature Chemical Biology · doi:10.1038/s41589-018-0161-x · Cited by 325
Marra, A., Trapani, D., Viale, G., Criscitiello, C., & Curigliano, G. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00197-2 · Cited by 317
Oh, D.-Y., Lee, K.-H., Lee, D.-W., Yoon, J., Kim, T.-Y., Bang, J.-H., Nam, A.-R., Oh, K.-S., Kim, J.-M., Lee, Y., et al. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00043-7 · Cited by 311
PD-L1 degradation pathway and immunotherapy for cancer
Gou, Q., Dong, C., Xu, H., Khan, B., Jin, J., Liu, Q., Shi, J., & Hou, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-03140-2 · Cited by 322
Heterogeneity of the tumor immune microenvironment and its clinical relevance
Jia, Q., Wang, A., Yuan, Y., Zhu, B., & Long, H. (2022) · Experimental Hematology & Oncology · doi:10.1186/s40164-022-00277-y · Cited by 300
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Hassel, J. C., Piperno-Neumann, S., Rutkowski, P., Baurain, J.-F., Schlaak, M., Butler, M. O., Sullivan, R. J., Dummer, R., Kirkwood, J. M., Orloff, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2304753 · Cited by 284
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 313
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Li, J., Duran, M. A., Dhanota, N., Chatila, W. K., Bettigole, S. E., Kwon, J., Sriram, R. K., Humphries, M. P., Salto-Tellez, M., James, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0387 · Cited by 312
“In line with its role modulating tumor immune responses, we found that ENPP1 expression within a given cancer type negatively correlates with its overall response rate to anti-PD1/PD-L1 therapy (35).”
BackgroundMolecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
“PDAC with a low number of genomic mutations is more resistant to PD-1 inhibitors than PDAC with a high number of genomic mutations [193].”
BackgroundLiu, B., Zhang, Y., Wang, D., Hu, X., & Zhang, Z. (2022) · Nature Cancer · doi:10.1038/s43018-022-00433-7 · Cited by 309
Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy
Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 306
“The sensitivity of MSI-high tumors to PD-1 blockademay be related to high TMB because TMB predicts checkpoint blockade response inmany cancer types (5, 9).”
BackgroundAntigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Wang, S., He, Z., Wang, X., Li, H., & Liu, X.-S. (2019) · eLife · doi:10.7554/elife.49020 · Cited by 312
“Immunotherapy clinical studies search strategy The dataset search strategy for assessment of cancer immunotherapy ORR) assessment has been described previously (Yarchoan et al., 2017).”
BackgroundMethodInfluentialImmunotherapeutic approaches for small-cell lung cancer
Iams, W. T., Porter, J., & Horn, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0316-z · Cited by 311
Grob, J.-J., Gonzalez, R., Basset-Seguin, N., Vornicova, O., Schachter, J., Joshi, A., Meyer, N., Grange, F., Piulats, J. M., Bauman, J. R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03054 · Cited by 301
“cSCC is considered an immunogenic cancer; it has the highest mutational burden exceeding that of classic head and neck squamous cell carcinoma (HNSCC), including mucosal tumors.(9,10) In cSCC, tumor suppressor genes are most frequently altered, with the UV signature a key mutational difference.”
BackgroundMolecular and nanoengineering approaches towards activatable cancer immunotherapy
Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 302
Lee, J. H., Shklovskaya, E., Lim, S. Y., Carlino, M. S., Menzies, A. M., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J. Y. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15726-7 · Cited by 288
“It will be interesting to explore whether these limitations in fl uence the predictive value of tumor mutation load, which has been shown to predict clinical bene fi t of immune checkpoint blockade in multiple cancers, including melanoma 61 – 63 .”
Chakravarty, D., Johnson, A., Sklar, J., Lindeman, N. I., Moore, K., Ganesan, S., Lovly, C. M., Perlmutter, J., Gray, S. W., Hwang, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02767 · Cited by 266
Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Hsu, J.-M., Li, C.-W., Lai, Y.-J., & Hung, M.-C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1892 · Cited by 286
“Despite PD-1/PD-L1 blockade therapy having shown remarkable clinical benefit, response rates to date have rarely exceeded 40% across multiple cancer types (3, 4).”
BackgroundSun, J.-Y., Zhang, D., Wu, S., Xu, M., Zhou, X., Lu, X.-J., & Ji, J. (2020) · Biomarker Research · doi:10.1186/s40364-020-00212-5 · Cited by 279
“[38] analyzed the objective response rates of PD-1/PD-L1 blockade therapy for the corresponding tumor mutation burden in various cancers, and their results showed that the mutation burden was closely associated with the objective response rate [38].”
C-Reactive Protein and Cancer—Diagnostic and Therapeutic Insights
Hart, P. C., Rajab, I. M., Alebraheem, M., & Potempa, L. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.595835 · Cited by 275
“Adaptive responses involve antibodies developed to specifically recognize malignant cells, and direct cytotoxic T-lymphocytes to specifically recognize intracellular abnormalities associated with uncontrolled cellular duplication that often display tumor specific antigens, leading to cell-mediated tumor cell apoptosis…”
BackgroundHack, S. P., Zhu, A. X., & Wang, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.598877 · Cited by 286
“However, mutation burden alone cannot explain the lack of response to anti–PD-1 treatment in MSS/ pMMR mCRC (15, 126).”
BackgroundImmunotherapy of Melanoma: Facts and Hopes
Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 281
Sholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 283
“Indeed, pancancer analyses reveal a statistical correlation between tumor mutation burden (TMB) and response rates and outcomes after PD-1 inhibitors.(12) Tumor mutations arise as a result of DNA damage from exogenous factors (tobacco smoke, ultraviolet light, DNA-damaging therapies) or as a result of defects in endog…”
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 278
Middleton, M. R., McAlpine, C., Woodcock, V. K., Corrie, P., Infante, J. R., Steven, N. M., Evans, T. R. J., Anthoney, A., Shoushtari, A. N., Hamid, O., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1247 · Cited by 275
“Overcoming peripheral tolerance through CPI or administration of cytokines has delivered long-term patient benefit in the treatment of some neoplasms (1), and AACRJournals.org Clin Cancer Res; 26(22) November 15, 2020 5873 Clin Cancer Res; 26(22) November 15, 2020 CLINICAL CANCER RESEARCH5874 these agents are changing…”
BackgroundInfluentialPeters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M. A., Talbot, T., Monnet, I., Hiret, S., Baas, P., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.01.074 · Cited by 264
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 249
“…have the potential to become the standard of care for both early and locally advanced dMMR CRCs. pMMR CRCs exhibit microsatellite stability and carry substantially fewer mutations than dMMR CRCs, which could explain the lack of response to ICB therapy in patients bearing this type of CRC 171 .”
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 256
“More importantly, many studies have demonstrated that PD-L1 and the TMB are biomarkers associated with the tumor response to combined ICIs [23,94,95,98].”
ResultAn Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma
Chen, Y., Li, Z.-Y., Zhou, G.-Q., & Sun, Y. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2166 · Cited by 268
“Besides, TMB has been recently evaluated as a potential biomarker predicting response to ICI therapy in prospective clinical trials and across many tumor types including HNSCC (37).”
BackgroundLin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
“A higher TMB is related to more new antigens produced by tumors, easier recognition by immune cells and a long-lasting clinical response [38].”
Background
Metadata
- Authors
- Yarchoan, M., Hopkins, A., & Jaffee, E. M.
- Affiliations
- Johns Hopkins University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-12-21
- Volume
- 377
- Issue
- 25
- Pages
- 2500-2501
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6549688
- OpenAlex
- W2779221466
- Cited by
- 3,230
- References
- 5
- Citations by year
- 2026: 181 · 2025: 274 · 2024: 410 · 2023: 460 · 2022: 525 · 2021: 558 · 2020: 408 · 2019: 255 · 2018: 153 · 2017: 1
- FWCI
- 98.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor mutational burden, anti-PD-1 therapy, PD-L1 blockade, immune checkpoint inhibitors, cancer immunotherapy response, predictive biomarkers, cancer types
- MeSH terms
- Antineoplastic Agents, DNA Mutational Analysis, Humans, Models, Genetic, Mutation, Neoplasms, Biomarkers, Tumor, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.